SP-A Peptide Therapeutic
Asthma (broad-spectrum, with focus on severe/eosinophilic phenotypes)
Pre-clinicalActive
Key Facts
Indication
Asthma (broad-spectrum, with focus on severe/eosinophilic phenotypes)
Phase
Pre-clinical
Status
Active
Company
About RaeSedo
RaeSedo is a private, preclinical-stage biotech developing SP-A-derived peptide therapeutics for asthma, targeting underlying inflammation and infection-driven exacerbations. The company's approach is based on the discovery that a subset of asthma patients have low or non-functional SP-A, a natural lung defense protein. Led by a team with expertise in lung immunology, clinical asthma, and business strategy, RaeSedo aims to address a critical unmet need in a large and costly disease market. The technology has shown promise in inducing eosinophil cell death and combating Mycoplasma pneumoniae infections, which are key drivers of severe asthma.
View full company profile